ronde-cel rondecabtagene autoleucel Updated Nov 6
The next major catalyst is the ASH 2026 Annual Meeting (December 12-15, 2026), where updated data from the PiNACLE pivotal trial (3L+) and the Phase 1/2 second-line cohort will be presented in oral and poster sessions. Strong data could drive the stock toward analyst targets (mean $37.88), while disappointing durability or safety signals would pressure shares. The pivotal data readout expected in mid-2027 and BLA submission in H2 2027 are the longer-term binary events.
- Ronde-cel's 91% ORR and 77% CR in 3L+ LBCL compare favorably to approved CAR T therapies, with a differentiated safety profile (no Grade >=3 CRS) that could support outpatient administration and a competitive advantage.
- The dual-targeting CD19/CD20 design and CD62L enrichment strategy may address the durability limitations of first-generation CAR T therapies, potentially offering longer-lasting responses.
- Analyst consensus is strongly bullish: 12 of 14 analysts rate it Buy/Strong Buy, with a mean price target of $37.88 (152.5% upside from the $15 close on Nov 5, 2026).
- Ronde-cel is still unapproved and faces a competitive market dominated by Yescarta (Gilead), Breyanzi (BMS), and Kymriah (Novartis), all established CD19 CAR T therapies with multi-billion-dollar sales and years of real-world data.
- The PiNACLE trial is single-arm (not randomized) in the 3L+ setting, which may raise the bar for FDA approval if durability data at the pivotal readout (mid-2027) does not clearly exceed existing therapies.
- The company is pre-revenue and posted a net loss of $45.5M in Q3 2026 alone. Despite the recent financing, additional dilution may be needed to fund commercialization.